Summary: The Centers for Medicare & Medicaid Services modified its obesity treatment coverage policy, effective May 15, 2026. Here's what billing teams need to do before that date.

CMS obesity treatment coverage policy has been a moving target for years, and this update continues that trend. The Centers for Medicare & Medicaid Services modified this policy with an effective date of May 15, 2026. This document does not list specific CPT or HCPCS codes — we'll address what that means for your billing team below. If you're billing for obesity-related services under Medicare, this change deserves your attention now.


Quick-Reference Table

Field Detail
Payer CMS
Policy Treatment of Obesity
Policy Code N/A
Change Type Modified
Effective Date May 15, 2026
Impact Level High
Specialties Affected Primary care, endocrinology, bariatric surgery, behavioral health, internal medicine, nutrition/dietetics
Key Action Review your obesity treatment billing workflows and medical necessity documentation before May 15, 2026

CMS Obesity Treatment Coverage Criteria and Medical Necessity Requirements 2026

CMS obesity treatment policy sits at the intersection of several program areas — intensive behavioral therapy, pharmacotherapy, and bariatric surgery — which makes this modification significant across multiple specialties.

The CMS coverage policy for obesity treatment has historically tied reimbursement to specific medical necessity thresholds. For most covered services, Medicare requires a body mass index (BMI) of 30 or higher. For bariatric surgical procedures, the threshold is typically a BMI of 35 or higher, combined with at least one obesity-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea.

Medical necessity documentation is not optional here — it is the line between payment and denial. Your notes must reflect the patient's BMI, the comorbid conditions present, and the treatment pathway chosen. If your documentation doesn't tell that story clearly, expect a claim denial.

Intensive Behavioral Therapy (IBT) for Obesity

Medicare covers Intensive Behavioral Therapy for obesity when delivered by a primary care physician or other qualified primary care practitioner in a primary care setting. The structure matters: one face-to-face visit per week for the first month, one visit every two weeks for months two through six, and monthly visits for months seven through twelve — but only if the patient achieves a 3-kg weight loss during the first six months.

That 3-kg threshold is a hard gate. If a patient doesn't hit it, Medicare stops covering additional IBT sessions. Your billing team should flag this in the patient record so clinicians know to document weight measurements at the six-month mark before billing subsequent visits.

Pharmacotherapy for Obesity

This is where the CMS coverage policy has been evolving most rapidly. The approval of GLP-1 receptor agonists — semaglutide (Wegovy), tirzepatide (Zepbound), and others — for weight management has put enormous pressure on CMS to clarify reimbursement. Historically, Medicare Part D excluded coverage for "drugs used for anorexia, weight loss, or weight gain." The Inflation Reduction Act and subsequent rulemaking have begun to chip away at that exclusion, particularly for GLP-1 drugs with cardiovascular indications.

Whether obesity pharmacotherapy is covered under Medicare depends heavily on the specific drug, the indication coded on the claim, and the patient's Part D plan formulary. If you're billing for GLP-1 therapy under a cardiovascular indication, the coverage rules differ from billing for the same drug under a pure obesity indication. These are not interchangeable on a claim, and conflating them is a fast path to audit risk.

Bariatric Surgery

CMS covers bariatric surgery procedures when a patient meets strict medical necessity criteria. Coverage exists for procedures performed at facilities certified by the American College of Surgeons or the American Society for Metabolic and Bariatric Surgery. Prior authorization requirements at the MAC level vary, so check with your regional Medicare Administrative Contractor before scheduling.

The real issue with bariatric surgery billing is documentation completeness before the claim goes out. CMS expects evidence of prior non-surgical weight loss attempts, psychiatric clearance in most cases, and nutritional counseling records. Missing any of these in the medical record creates denial exposure.


CMS Obesity Treatment Exclusions and Non-Covered Indications

Not everything related to obesity treatment qualifies for Medicare reimbursement. CMS draws clear lines, and crossing them without documentation generates denials that are hard to appeal.

Weight loss drugs for obesity alone remain excluded from most Medicare Part D plans unless the drug carries an additional FDA-approved indication (such as cardiovascular risk reduction) that the plan has opted to cover. This is a distinction your pharmacy billing team and your medical billing team both need to understand — it affects both professional and pharmacy claims.

Commercial weight loss programs — think medically supervised diet programs that aren't delivered by a covered provider in a covered setting — are not reimbursable under Medicare. Patients pay out of pocket for these. If a clinician in your practice participates in or refers to such a program, make sure you're not inadvertently bundling those services into a covered claim.

Behavioral counseling delivered outside a primary care setting doesn't meet the IBT coverage criteria. The setting requirement is real. A psychologist or behavioral health specialist delivering weight loss counseling in a specialty setting bills under different rules — and may not be reimbursable for obesity treatment under the IBT benefit at all.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Intensive Behavioral Therapy (IBT) for obesity, primary care setting Covered Not listed in this policy document BMI ≥ 30 required; structured visit schedule; 3-kg weight loss gate at 6 months
Bariatric surgery for severe obesity with comorbidity Covered Not listed in this policy document BMI ≥ 35 + comorbidity; facility certification required; prior auth may apply by MAC
GLP-1 receptor agonists for obesity with cardiovascular indication Covered (with conditions) Not listed in this policy document Coverage depends on FDA indication, Part D plan, and specific drug
+ 4 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Note: This policy document does not list specific CPT, HCPCS, or ICD-10 codes. The code information above reflects general Medicare billing knowledge for these indications, not codes published in this specific policy revision.


This policy is now in effect (since 2026-05-15). Verify your claims match the updated criteria above.

CMS Obesity Treatment Billing Guidelines and Action Items 2026

The effective date of May 15, 2026 gives you a concrete deadline. Here's what to do before then.

#Action Item
1

Pull your obesity treatment claims from the past 12 months and audit for medical necessity documentation. Look specifically for BMI documentation, comorbidity coding, and prior treatment history in the medical record. If the chart doesn't support the claim, you're exposed.

2

Verify your IBT billing workflow against the structured visit schedule. Code the correct visit type for each phase of therapy. Confirm that your EHR or billing system flags the six-month weight measurement requirement so the 3-kg threshold gets documented before you bill month seven and beyond.

3

Separate your GLP-1 claims by indication before May 15, 2026. If your practice or your affiliated pharmacy is billing GLP-1 drugs, confirm that the primary diagnosis code on each claim reflects the FDA-approved indication under which coverage exists. Obesity billing and cardiovascular risk reduction billing are different — treat them that way.

+ 4 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

If your practice has significant volume in bariatric surgery, obesity pharmacotherapy, or IBT, talk to your compliance officer before the May 15, 2026 effective date. The intersection of Part B and Part D coverage rules here is genuinely complex, and the financial exposure from systematic miscoding is real.


Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Obesity Treatment Under CMS Policy

Important note: This CMS policy document does not list specific CPT, HCPCS, or ICD-10 codes. We do not fabricate or infer codes from policy titles. For the exact codes covered under this modified policy, access the full policy document at the CMS source or contact your Medicare Administrative Contractor directly.

Your billing team should cross-reference current CMS billing guidelines, the Medicare Claims Processing Manual (Chapter 18 for preventive services, Chapter 32 for billing), and any applicable LCDs from your MAC to identify the specific codes in scope.

This is a case where verifying codes through the primary source — not a secondary summary — matters for your reimbursement accuracy.


Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee